Advanced hepatocellular carcinoma and successfully targeted the first‑line treatment with atezolizumab and bevacizumab according to IMbrave150 trial

03/2021

Prof. MUDr. Samuel Vokurka, Ph.D.

Onkologická a radioterapeutická klinika LF UK a FN Plzeň

SUMMARY

Hepatocellular carcinoma is a prognostically unfavorable malignancy with very limited possibilities to influence its course, especially in advanced stages of the disease. Treatment with atezolizumab and bevacizumab in the IMbrave150 study showed a significant prolongation of median progression and overall survival of 19,2 versus 13,4 months in sorafenib group of patients (HR 0,66; p = 0,0009). This has been the longest survival observed in the first-line phase III study in advanced hepatocellular carcinoma, so far.

Key words

hepatocellular carcinoma, atezolizumab, bevacizumab, targeted therapy